A5085339321- Gallbladder and Bile Duct Disorders
- Biliary and Gastrointestinal Fistulas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Venous Thromboembolism Diagnosis and Management
- Myasthenia Gravis and Thymoma
- Gastrointestinal disorders and treatments
- Lymphatic Disorders and Treatments
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Congenital Diaphragmatic Hernia Studies
- Diagnosis and Treatment of Venous Diseases
- Diverticular Disease and Complications
- Pancreatic and Hepatic Oncology Research
- Liver Diseases and Immunity
- Oral and gingival health research
- Amoebic Infections and Treatments
- Pediatric Hepatobiliary Diseases and Treatments
Kepler Universitätsklinikum
2024
Johannes Kepler University of Linz
2024
Innsbruck Medical University
2023
Universität Innsbruck
2023
To analyze clinical and autopsy findings in patients with malignant biliary obstruction treated endoprostheses.Stents were inserted endoscopically nine transhepatically 50. In 24 patients, was performed; 22 cases, histologic analysis of the area which stent placed available.The technical success rate 100%, 92%. Complications occurred 16 one procedure-related death. The severe complications 19%, primarily due to acute cholangitis (n = 9). Mean survival time 175 days. Stent found 12 on average...
mGEC is associated with poor overall survival (OS) of approximately 4–10 months. CtDNA emerging as a promising prognostic biomarker high potential for early relapse detection. However, until now, there was little knowledge on serial ctDNA detection and its impact treatment evaluation prognosis in mGEC. Methods: (ddPCR) carried out serially 37 matched tissue (NGS) patients prior to systemic initiation every two weeks thereafter restaging (n = 173 samples). The results have been correlated...
Background Even though it is rare, chylothorax represents a major complication after anatomical lung resections with lymphadenectomy. Moreover, optimal treatment still matter of debate. Aim this study was to evaluate prevalence, risk factors and therapy outcomes in VATS cohort primary cancer.